NICE decision on flu drug

Healthcare Market News (News) October 1999 The National Institute for Clinical Excellence (NICE) has recommended that the flu drug Relenza, developed by Glaxo Wellcome, should not be made available on the NHS. Relenza is the first drug to be subjected to appraisal by NICE. Andrew Dillon, chief executive of NICE, said: ‘The Institute’s guidance to…

You must be a HM Subscriber to view this content.

Subscribe Now »